Amanta Healthcar Q1 FY27 Results (NSE: AMANTA)
Signal: Steady quarter
The read
Q1FY27 established a ₹68.8 crore revenue base, ₹15.18 crore EBITDA and ₹3.31 crore PAT, while the 22.1% EBITDA margin and ₹0.85 EPS have no disclosed YoY or QoQ comparatives; the key trajectory question is therefore whether this margin and profit base are repeatable.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹68.8 Cr | N/A | N/A |
| EBIT | ₹10.5 Cr | N/A | |
| Net profit | ₹3.31 Cr | N/A | |
| EPS | ₹0.85 | N/A | |
| EBIT margin | 22.1% |
P&L walk
Standalone Q1FY27 revenue was ₹68.8 crore and EBITDA was ₹15.18 crore at a 22.1% margin; EBIT of ₹10.5 crore converted to PAT of ₹3.31 crore, with no YoY or QoQ comparative columns disclosed.
Key positives
- Standalone Q1FY27 EBITDA was ₹15.18 crore at a 22.1% margin, providing a measurable operating-profit base despite the absence of comparative periods.
- Basic and diluted EPS were both ₹0.85, with no disclosed gap between the two measures.
- The limited review report carried an unmodified opinion for the quarter ended June 30, 2026.
Key concerns
- No YoY or QoQ comparative figures were disclosed for ₹68.8 crore revenue, 22.1% EBITDA margin, ₹3.31 crore PAT or ₹0.85 EPS, limiting assessment of momentum and repeatability.
- The filing does not disclose pharma-specific operating KPIs such as geography mix, product launches, approvals, R&D intensity or volume growth.
Research and educational content only. Not investment advice.